Over-the-counter Painkillers Were Associated With Better Concussion Recovery
The study merely demonstrates a connection rather than proving that painkillers enhance concussion recovery.
Roche’s Supplemental Biologics License Application of Gazyva/Gazyvaro (Obinutuzumab) for The Treatment of Lupus Nephritis Accepted by U.S. FDA
In a randomized phase III study, Gazyva®/Gazyvaro® is the only anti-CD20 monoclonal antibody that shows a full renal response benefit.
AbbVie Enters Into the Obesity Drug Market With a License Agreement
GUB014295 is a calcitonin and amylin receptor-specific agonist that may be a long-acting amylin analog.
BEACON-IPF Clinical Trial for Idiopathic Pulmonary Fibrosis Discontinued With Available Results
The BEACON-IPF Phase 2b trial, which was assessing bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), has been discontinued by Pliant Therapeutics, Inc. after a [Read More…]
What is a Bioreactor? Explanation and Structure
Bioreactors are specialized containers that allow the controlled development of cells, enzymes, or microbes. Environmental engineering, biotechnology, and pharmaceuticals are just a few of the [Read More…]
“Healthy Skepticism” A New Ad Campaign from Lilly Against Compounded Drugs
Two blockbuster weight loss drugs including Lilly’s Zepbound were in U.S. FDA’s drugs shortage list.
Based on Results From the Phase 3 BRUIN CLL-321 trial, Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union
The European Commission is currently taking final action on the application for the use of Jaypirca in patients with relapsed or refractory CLL who have received prior treatment with a BTK inhibitor as a result of this favorable view.
Amyotrophic Lateral Sclerosis Can be Diagnosed With Blood Test
Three blood biomarker categories were evaluated in the study: phosphorylated tau 181, glial acidic proteins, and neurofilament light chain proteins.
Merck’s Application for KEYTRUDA® (pembrolizumab) Receives US FDA’s Priority Review
American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the [Read More…]
New Skin Disease was Discovered Using an Innovative Diagnostic Platform
Many Americans suffer from long-term inflammatory skin disorders that have no known etiology and frequently no effective treatments other than symptom control. A recent study [Read More…]
